A Study of NX-1607 in Adults With Advanced Malignancies
A legfontosabb adatok
- Ki végzi
- Nurix Therapeutics, Inc.
- Hol
- Cambridge, Glasgow, London, Manchester, Newcastle, Oxford és Sutton (Egyesült Királyság)Mind a 7 helyszín megnézéseMég 1 másik országban, 10 helyszínen
- Azonosító
- Állapot
- Toboroz
- Fázis
- 1. fázis
- Résztvevők
- 345 fő, tervezett
- Kezdés
- 2021. szept. 29.
- Várható befejezés
- 2028. febr. 28.
- A vizsgálat típusa
- Beavatkozással járó, 12 csoport
- A vizsgált kezelések
- NX-1607
- Paclitaxel
- A regiszteradat frissítve
- 2025. szeptember 9.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
A vizsgálat olyan felnőtteket keres, akiknek előrehaladott daganatuk van, amely szétterjedt vagy műtéttel nem eltávolítható, és már kaptak szokásos kezelést, vagy nem kaphatnak.
- Életkor
- 18 év vagy idősebb
- Nem
- Mindkét nemű résztvevő csatlakozhat.
- A betegség stádiuma
- Szétterjedt vagy műtéttel nem eltávolítható, mérhető daganat az alábbi típusok egyikében: platinarezisztens petefészekrák, gyomor-/GEJ-rák, fej-nyaki laphámrák, melanóma, NSCLC, mCRPC, mesothelioma, hármasnegatív emlőrák, urothelialis rák, méhnyakrák, MSS vastagbélrák vagy DLBCL. ECOG-teljesítménystátusz 0 vagy 1.
- Korábbi kezelés
- Kapnia kellett szokásos kezelést, vagy nem kaphat ilyet. Az utolsó szisztémás daganatellenes kezelés óta legalább 3 hétnek vagy 5 felezési időnek (amelyik rövidebb) kell eltelnie, az utolsó sugárkezelés óta pedig 2 hétnek.
A részvétel fő kizáró okai
- Aktív, kezeletlen agyi áttét
- Terhesség, szoptatás vagy tervezett teherbeesés
- Az elmúlt 2 évben kezelt aktív autoimmun betegség, vagy uveitis a kórtörténetben
- Szívinfarktus, instabil angina vagy súlyos szívelégtelenség az elmúlt 6 hónapban
- Aktív A-, B- vagy C-típusú hepatitis
A regiszter feltételei, szó szerint
Mind a 34 feltétel megnézéseKevesebb
Ki vehet részt
- Age ≥ 18 years
- Measurable disease per disease-specific response criteria
- Patients must have disease that is metastatic or unresectable and have received standard treatment options, are not candidates for standard treatment options, or will otherwise be prevented from receiving any standard treatment options
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Minimum of 3 weeks or 5 half-lives (whichever is shorter) since last dose of systemic cancer therapy (unless otherwise specified) or minimum of 2 weeks since last radiotherapy, or minimum of 6 weeks since last systemic therapy with nitrosoureas, antibody-drug conjugate, or radio immuno-conjugate therapy
- Adequate organ and bone marrow function, in the absence of growth factors (with limited exception for DLBCL), as defined by laboratory parameters
- Patients of child-bearing potential must use adequate contraceptive measures to avoid pregnancy for the duration of the study as defined in the protocol
- Patient must be willing and able to adhere to the prohibitions and restrictions specified in the protocol
- Each patient must sign an informed consent form (ICF)
- Histological or cytological diagnosis of platinum-resistant EOC, including primary peritoneal and fallopian tube carcinoma; gastric/GEJ cancer; HNSCC; recurrent and either metastatic or unresectable melanoma; NSCLC; mCRPC; MPM; TNBC; locally advanced or metastatic urothelial cancer; cervical cancer; MSS CRC; or DLBCL (including DLBCL-RT)
- Accessible tumor (for all cohorts) or lymph node (DLBCL only) for biopsy (Phase 1b only)
Ki nem vehet részt
- History of CAR-T therapy within 30 days prior to the first dose of NX-1607
- Toxicities from previous anti-cancer therapies that have not resolved to baseline levels or to Grade 1 or less except for Grade 2 alopecia and Grade 2 peripheral neuropathy or patients receiving endocrine replacement therapy
- Patients who experienced Grade 3 or higher irAEs with prior immunotherapy
- Patient has had major surgery (e.g., requiring general anesthesia) within 4 weeks before the planned first dose of NX-1607, or will not have fully recovered from surgery, or has surgery planned during the time the patient is expected to participate in the study or within 4 weeks after the last dose of NX-1607. Note: Patients with minor planned surgical procedures to be conducted under local anesthesia may participate
- Vaccinated with a live vaccine within 28 days (with the exception of the annual inactivated influenza vaccine) or COVID-19 vaccination within 14 days prior to the first dose of NX-1607
- Current active hepatitis, including hepatitis A (hepatitis A virus immunoglobulin M [IgM] positive), hepatitis B (hepatitis B virus [HBV] surface antigen positive), or hepatitis C (hepatitis C virus [HCV] antibody positive, confirmed by HCV RNA). Patients with HCV with undetectable virus after treatment are eligible. Patients with prior exposure to HBV may be entered if quantitative PCR is negative
- Use of systemic corticosteroids (> 20 mg prednisone or equivalent) within 15 days (except for prophylaxis for radio diagnostic contrast reactions and/or prophylaxis for patients receiving paclitaxel), or other immunosuppressive drugs within 30 days, prior to the first dose of NX-1607
- Use of biotin (i.e., Vitamin B7) or supplements containing biotin higher than the daily adequate intake of 30 µg [NIH 2020] (Note: Patients who switch from a high dose to a dose of 30 µg/day or less at least 1 day prior to Screening assessments are eligible for study entry)
- Receipt of an IP or has been treated with an investigational device within 3 weeks or 5 half-lives (whichever is shorter) prior to the first dose of NX-1607
- Uncontrolled intercurrent illness including, but not limited to, poorly controlled hypertension or diabetes, or ongoing active infection requiring systemic therapy
- Psychiatric illness that would limit compliance with study requirements
- History of uveitis, or an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed
- Unable to swallow capsules or has malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction likely to interfere with the delivery, absorption, or metabolism of NX-1607
- Known allergies, hypersensitivity, or intolerance to components of NX-1607
- Infection with human immunodeficiency virus (HIV)-1 or HIV-2. Exception: Patients with well controlled HIV (e.g., CD4 > 350/mm3 and undetectable viral load) are eligible
- Treatment with any of the following prior to the first dose of NX-1607: CPI (anti-PD-1, PD-L1, cytotoxic T-lymphocyte-associated protein 4, etc) within 3 weeks; autologous or allogeneic stem cell transplant within 100 days; prior systemic cancer therapy within 3 weeks or 5 half-lives (whichever is shorter) (unless otherwise specified) (including hormonal therapy except for hormonal prophylaxis for a prior malignancy); prior radiotherapy within 2 weeks; prior systemic therapy with nitrosoureas, antibody-drug conjugate, or radio-immuno-conjugate therapy within 6 weeks; use of strong or moderate CYP3A4 inducers or inhibitors within 14 days or 7 days, respectively, or 5 half-lives (whichever is longer)
- Any of the following within 6 months prior to the first dose of NX-1607 or ongoing:; Myocardial infarction; Unstable angina; Unstable symptomatic ischemic heart disease; New York Heart Association Class III or IV heart failure; Thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events); Any other significant cardiac condition (e.g., pericardial effusion, restrictive cardiomyopathy, severe untreated valvular stenosis, or severe congenital heart disease); Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating Investigator in consultation with the Medical Monitor
- Active known second malignancy with the exception of any of the following:; Adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical cancer; Adequately treated Stage I cancer from which the patient is currently in remission and has been in remission for ≥ 2 years; Low-risk prostate cancer with Gleason score < 7 and PSA < 10 ng/mL; Any other cancer from which the patient has been disease-free for ≥ 2 years
- Active untreated brain metastases
- Patient has any of the following:
- Patients with primary refractory EOC defined as patients who do not respond to their first platinum-containing regimen or who relapse less than 6 months after completion of that first platinum-containing regimen
- Pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 6 months after the last dose of NX-1607
- Patient is a man who plans to father a child while enrolled in this study or within 3 months after the last dose of NX-1607 and, as applicable, within 6 months after the last dose of paclitaxel
Helyszínek itt: Egyesült Királyság
Még 1 másik országban, 10 helyszínen
- Addenbrookes Cambridge University HospitalCambridge, Egyesült KirályságContact: Nurix Therapeutics Patient OutreachRésztvevőt keres
- Beatson West of Scotland Cancer CentreGlasgow, Egyesült KirályságContact: Ruth OrrRésztvevőt keres
- Sarah Cannon Research InstituteLondon, Egyesült KirályságContact: ReferralsRésztvevőt keres
- The Christie NHS Foundation TrustManchester, Egyesült KirályságContact: The Christie EnquiriesRésztvevőt keres
- Northern Centre for Cancer CareNewcastle, Egyesült KirályságContact: Nurix Therapeutics Patient OutreachRésztvevőt keres
- Churchill HospitalOxford, Egyesült KirályságContact: Nurix Therapeutics Patient OutreachNo longer taking part
- Royal Marsden Hospital NHS Foundation TrustSutton, Egyesült KirályságContact: Nurix Therapeutics Patient OutreachRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
A vizsgálat 12 csoportja
- Phase 1a Dose Escalation of NX-1607 (monotherapy)A vizsgált kezelés
Multiple dose levels and dosing regimen of NX-1607 to be evaluated; determination of MTD/Phase 1b recommended dose.
Kezelés: NX-1607
- Phase 1a Food EffectA vizsgált kezelés
Impact of food on NX-1607 bioavailability and tolerability to be evaluated
Kezelés: NX-1607
- Phase 1b Dose Expansion in platinum-resistant EOCA vizsgált kezelés
Patients with platinum-resistant EOC, including primary peritoneal and fallopian tube carcinoma
Kezelés: NX-1607
- Phase 1b Dose Expansion in advanced gastric/GEJ cancerA vizsgált kezelés
Patients with recurrent, locally advanced, or metastatic gastric or GEJ adenocarcinoma
Kezelés: NX-1607
- Phase 1b Dose Expansion in HNSCCA vizsgált kezelés
Patients with recurrent, locally advanced, or metastatic HNSCC
Kezelés: NX-1607
- Phase 1b Dose Expansion in recurrent melanomaA vizsgált kezelés
Patients with recurrent and either metastatic or unresectable Melanoma
Kezelés: NX-1607
- Phase 1b Dose Expansion in advanced NSCLCA vizsgált kezelés
Patients with Stage IV NSCLC
Kezelés: NX-1607
- Phase 1b Dose Expansion in mCRPCA vizsgált kezelés
Patients with mCRPC who received a minimum of 2 prior lines of therapy in the advanced setting including androgen receptor-directed therapy and a taxane-based chemotherapy and has PSA or radiographic progression
Kezelés: NX-1607
- Phase 1b Dose Expansion in mixed solid tumor cohortA vizsgált kezelés
Cohort of mixed solid tumor indications consisting of patients with MPM, TNBC, locally advanced or metastatic urothelial cancer, cervical cancer, or DLBCL/DLBCL-RT
Kezelés: NX-1607
- Phase 1a Dose Escalation of NX-1607 in combination with PaclitaxelA vizsgált kezelés
Indications may include but are not limited to, platinum resistant EOC, gastric/GEJ cancer. HSNCC, NSCLC, TNBC, locally advanced or metastatic urothelial cancer and cervical cancer.
Kezelés: NX-1607 és Paclitaxel
- Phase 1b Dose Expansion of NX-1607 in combination with PaclitaxelA vizsgált kezelés
Indications may include but are not limited to, platinum resistant EOC, gastric/GEJ cancer, HSNCC, NSCLC, TNBC, and locally advanced or metastatic urothelial cancer and cervical cancer
Kezelés: NX-1607 és Paclitaxel
- Phase 1b Dose Expansion in MSS CRCA vizsgált kezelés
Patients with histologically confirmed MSS CRC, known KRAS WT, and must have been previously treated with \> = 2 lines of systemic therapy including a fluoropyrimidine, irinotecan, and/or oxaliplatin (and EGFR inhibitor if known Ras wild type)
Kezelés: NX-1607
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase 1b Expansion in Select Tumor Types
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 12.
- A regiszteradat frissítve
- 2025. szeptember 9.